ETEfthymios Triantafyllou

Efthymios Triantafyllou

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Efthymios Triantafyllou has a total of 33 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Overlap of Afferent Baroreflex Failure and Lower Cranial Neuropathies in Long-term Oropharyngeal Cancer Survivors Post-Radiation Therapy: Secondary Analysis of a Prospective Registry Cohort

    by Efthymios Triantafyllou, Isabelle Jang, Ariana J Sahli, Patrik J. Van-Bergen, Amy C. Moreno, Anita Deswal, Elie Mouhayar, Clifton D. Fuller, Katherine A. Hutcheson, Efstratios Koutroumpakis

  • Open Access

    Early anthracycline cardiotoxicity in adolescents and young adults with sarcoma: a prospective echocardiographic study

    by Efstratios Koutroumpakis, Efthymios Triantafyllou, John Andrew Livingston, Juhee Song, Claire Viguet, Andres Hughes, Savannah V Rauschendorfer, Prince Jeyabal, Theresa A Honey, Joya Chandra, et al.

    Background: Adolescents and young adults (AYAs) with sarcomas often receive high-dose doxorubicin (Dox), but data on early cardiotoxicity in this population are limited. Objectives: To prospectively evaluate early echocardiographic changes in AYAs with sarcoma treated with high-dose Dox. Methods: AYAs (15–39 years) with sarcoma treated at a tertiary cancer centre (2018–22) were prospectively enroled. Echocardiograms were performed at baseline, 1 and 2 years after cancer therapy initiation and interpreted by a single cardiologist. The primary endpoint was a >10% absolute reduction in left ventricular ejection fraction (LVEF), an absolute LVEF 10% decrease in LV wall thickness/dimension (LVWT/D) ratio from baseline. Secondary endpoints included longitudinal changes in cardiac structure, chamber volumes, systolic and diastolic function, and strain. Results: Of 70 patients, 56 completed at least two of three study echocardiograms (median age 22.6 [IQR, 17.6–30.5] years; 41% female, 84% white). Median cumulative Dox dose was 450 (IQR, 370–450) mg/m2; 75% received dexrazoxane. The primary endpoint was met by 44.4% at 1 year and 27.5% at 2 years, driven primarily by LVWT/D ratio decline (37% at 1 year, 25% at 2 years), while significant LVEF decline was observed in 11.1% and 2.5%, respectively. Significant absolute changes at 1 year included LVEF (−2.73 ± 4.3%, P < .001), global longitudinal strain magnitude (−1.37 ± 2.56%, P = .002), septal e′ (−1.75 ± 2.48 cm/s, P < .001), and lateral e′ (−2.78 ± 3.44 cm/s, P < .001), persisting at 2 years. One patient (1.8%) developed ventricular fibrillation and heart failure with reduced ejection fraction, with LVEF recovery within 1 year. Conclusions: Over one-third of AYAs with sarcoma met the primary endpoint at 1 year, with half of these abnormalities persisting at 2 years, primarily driven by LVWT/D ratio reductions. Subclinical changes in strain and diastolic function were observed, reflecting the broad cardiac impact of high-dose Dox in this population.


  • Open Access

    Estrogen-Receptor-Low-Positive Breast Cancer: Pathological and Clinical Perspectives

    by Christina Panagiotis Malainou, Nikolina Stachika, Aikaterini Konstantina Damianou, Aristotelis Anastopoulos, Ioanna Ploumaki, Efthymios Triantafyllou, Konstantinos Drougkas, Georgia Gomatou, Elias Kotteas

    The expression of estrogen receptors (ERs) in breast cancer (BC) represents a strong prognostic and predictive biomarker and directs therapeutic decisions in early and advanced stages. ER-low-positive BC, defined by the immunohistochemical (IHC) expression of ERs from 1% to 9%, constitutes a distinct subset of total BC cases. Guidelines recommend that a low expression of ERs be reported in pathology reports since the benefit of endocrine therapy in patients with ER-low-positive BC is uncertain. Recently, several cohorts, mostly of a retrospective nature, have been published, reporting the clinicopathological characteristics and outcomes of ER-low-positive BC. However, the majority of the data focus on early-stage BC and the use of (neo)adjuvant therapy, and there is a significant lack of data regarding metastatic ER-low-positive BC. Further factors, including tumor heterogeneity as well as the potential loss of ER expression due to endocrine resistance, should be considered. Including patients with ER-low-positive BC in clinical trials for triple-negative breast cancer (TNBC) might improve the understanding of this entity and allow novel therapeutic approaches. The design and conduction of randomized clinical trials regarding this subgroup of patients are greatly anticipated.